PLAINSBORO, N.J., March 25, 2014 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the expansion of its skin and wound product line with the introduction of Integra® Wound Matrix (Thin). Integra Wound Matrix (Thin) has received 510(k) clearance from the United States Food and Drug Administration (FDA) and expects to begin a full market release in the United States in April 2014. Integra's newest skin product will be featured at the American Burn Association Annual Meeting, March 25 – 28, 2014, in Boston, Massachusetts.
"Integra Wound Matrix (Thin) is a very exciting opportunity for Integra," said William Weber, Vice President and General Manager, Integra Extremity Reconstruction. "Our new, thinner product has approximately half the thickness of Integra Wound Matrix and reflects our commitment to offer surgeons enhanced treatment options. The thinner matrix can be applied to complex anatomical sites that require a more conformable graft."
Integra Wound Matrix (Thin) is a collagen-glycosaminoglycan wound matrix that maintains and supports a healing environment for wound management. Available in a variety of sizes, it may be used for second degree burns, partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/grafts, post-Moh's surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, skin tears) and draining wounds. Terminally sterilized, Integra Wound Matrix (Thin) is conveniently stored at room temperature, has a 24-month shelf life, and is intended for one-time use.
Integra offers a versatile range of skin repair solutions to meet the surgeon's procedural needs, including Integra® Dermal Regeneration Template, one of the first regenerative medicine products approved by the FDA; Integra® Meshed Bilayer Wound Matrix, which can be used with Negative Pressure Wound Therapy; and Integra® Flowable Wound Matrix, designed for easy application to tunneled and/or undermined wounds. Together, these products represent over 30 years of science and innovation in the development of collagen technology. Integra's Ultra Pure Collagen™ is the base material of implants used successfully in over 12 million procedures.
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. For more information, please visit www.integralife.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2013 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
Source:Integra LifeSciences Holdings Corp.